ArticleNature communications2023
CD98hc is a target for brain delivery of biotherapeutics.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
19.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 80 citations in OpenAlex.
- Article
- Article
- Huntingtin Aggregate-Responsive Autophagy Gene Circuit Mitigates Disease Pathology in R6/2 Mice.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Antibody-Based Biologics for CNS Disorders.Antibodies (Basel, Switzerland) · 2026Review
- Antisense oligonucleotide treatment following viral delivery of artificial SOD1-targeting miRNA shows improved efficacy in SOD1-G93A mice.Molecular therapy. Advances · 2026Article
- CA-IV-directed small-molecule shuttle enables targeted brain delivery of biologics.Nature chemical biology · 2026Article
- Spatiotemporal arising of molecular and functional blood-brain barrier properties in the developing Gallus gallus optic tectum.Fluids and barriers of the CNS · 2026Article
- Breaking the Silent Barrier: Engineering Antibodies for Brain-Targeted Rabies Immunotherapy.Pharmaceutics · 2026Review
- Engineering bispecific antibodies for brain delivery of biotherapeutics in multiple species.Nature biomedical engineering · 2026Article
- CD98hc-targeted antibody shuttles for central nervous system delivery with broad cross-species reactivity.Nature biomedical engineering · 2026Article
- Potent anti-tumor activity of CD98hc-targeted antibody-drug conjugates in ovarian cancer.Signal transduction and targeted therapy · 2026Article
- CD98hc controls CNS angiogenesis and blood-brain barrier integrity through localized regulation of the systemic integrin-FAK pathway.Nature cardiovascular research · 2026Article
- Therapeutic targeting of neuroimmune mechanisms in neurodegeneration.Nature reviews. Drug discovery · 2026Review
- Mucin-binding protein shuttles enable delivery of brain-targeted therapeutics.bioRxiv : the preprint server for biology · 2026Article
- Bioconjugates for improved delivery of oligonucleotide therapeutics to the central nervous system.Advanced drug delivery reviews · 2026Review
- Bridging the blood-brain barrier: strategies to improve delivery of biologics to tumors in the brain.Fluids and barriers of the CNS · 2026Review
- Complement in brain and eye disease: shared mechanisms, convergent pathologies, and common therapeutic opportunities.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Review
- A fully iPS-cell-derived 3D model of the human blood-brain barrier for exploring neurovascular disease mechanisms and therapeutic interventions.Nature neuroscience · 2026Article
- H-ferritin nanoparticle-mediated antibody delivery across the blood-brain barrier.Frontiers in aging neuroscience · 2026Article
- A SynB1-conjugated antibody cocktail crosses the blood-brain barrier to produce a therapeutic effect on rabies.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
50 authors at 3 institutions in 1 country.
Kylie S Chew *Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Robert C Wells *Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Arash MoshkforoushDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Darren ChanDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Kendra J LechtenbergDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Hai L TranDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.ORCID http://orcid.org/0000-0003-3715-8111
Johann ChowDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.ORCID http://orcid.org/0009-0001-8170-6392
Do Jin KimDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Yaneth Robles-ColmenaresDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Devendra B SrivastavaDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Raymond K TongDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Mabel TongDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Kaitlin XaDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Alexander YangDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Yinhan ZhouDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Padma AkkapeddiDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Lakshman AnnamalaiDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Kaja BajcDepartment of Pharmacology, University of California San Diego, 9500 Gilman Dr., La Jolla, 92093, CA, USA.
Marie BlanchetteDepartment of Pharmacology, University of California San Diego, 9500 Gilman Dr., La Jolla, 92093, CA, USA.
Gerald Maxwell CherfDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Timothy K EarrDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Audrey GillDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
David HuynhDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
David JoyDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.ORCID http://orcid.org/0000-0001-9941-9538
Kristen N KnightDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Diana LacDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Amy Wing-Sze LeungDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Katrina W LexaDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Nicholas P D LiauDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Isabel BecerraDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Mario MalfavonDepartment of Pharmacology, University of California San Diego, 9500 Gilman Dr., La Jolla, 92093, CA, USA.
Joseph McInnesDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Hoang N NguyenDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.ORCID http://orcid.org/0000-0001-6608-7581
Edwin I LozanoDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Michelle E PizzoDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.ORCID http://orcid.org/0000-0003-4219-5996
Elysia RocheDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Patricia SacayonDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Meredith E K CalvertDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Richard DanemanDepartment of Pharmacology, University of California San Diego, 9500 Gilman Dr., La Jolla, 92093, CA, USA.
Mark S DennisDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Joseph DuqueDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Kapil GadkarDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Joseph W LewcockDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.ORCID http://orcid.org/0000-0003-3012-7881
Cathal S MahonDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
René MeisnerDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Hilda SolanoyDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Robert G ThorneDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Ryan J WattsDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Y Joy Yu ZucheroDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA. zuchero@dnli.com.
Mihalis S KariolisDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA. kariolis@dnli.com.ORCID http://orcid.org/0000-0003-2067-4013
Denali Therapeutics (United States) · USUniversity of California San Diego · USUniversity of Minnesota · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain exposure of systemically administered biotherapeutics is highly restricted by the blood-brain barrier (BBB). Here, we report the engineering and characterization of a BBB transport vehicle targeting the CD98 heavy chain (CD98hc or SLC3A2) of heterodimeric amino acid transporters (TV
Indexed as
Blood-Brain BarrierBrainAnimalsAntibodiesEngineeringMacaca fascicularisMiceTissue DistributionAntibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.